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Cannabinoids A’-tetrahydrocannabinol, cannabinol, cannabidiol and cannabigerol have been shown to af- 
fect directly the activity of phospholipase A, in a cell-free assay. The compounds produced a biphasic activa- 
tion of the enzyme, with EC,, values in the range 6.&20.0 x 10e6 M and IC, values in the range 5O.s 
150.0 x lo+ M. These results correlated well with the relative potencies reported for the st~m~ation of pros- 
taglandin release from human synovial cells in vitro, confirming that activation of phospholipase A, is the 
predominant action of cannabinoids on arachidonate metabolism in tissue culture. However, since A’-tetra- 
hydrocannabinol is unique among these compounds in possessing cataleptic activity, it is unlikely that phos- 
pholipase A, is the major receptor mediating the psychotropic effects of cannabis. 
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1. INTRODUCTION tivation of phospholipase AZ and cycloxygenase. 
There is evidence that prostagl~dins (PCs) are 
mediators of the central effects of Ar-tetrahydro- 
cannabinol (THC), the psychoactive constituent of 
Cannabis safiva L. For example, the cataleptic ef- 
fects of THC in mice are abolished by treatment 
with aspirin, indomethacin, diflunisal and 
phenylbut~one, agents which inhibit PC syn- 
thesis. Catalepsy can be restored by the ad- 
ministration of exogenous PGEs [ 11. In addition, 
the stimulation of arachidonate metabolism by 
cannabinoids in cell culture systems has been cor- 
related with the psychotropic potency of THC 
analogues [Z]. Burstein and co-workers [3] have 
proposed that THC interacts with specific sterol 
binding sites in the plasma membrane, causing ac- 
Since it is probable that the cannabinoids affect the 
activity of several enzymes in the arachidonate 
cascade 141, it was decided to investigate the ac- 
tions of these compounds on phospholipase A2 in 
a cell free system, and to determine whether direct 
effects on this enzyme were responsible for the 
observed pharmacological activity of cannabinoids 
both in vitro and in vivo. 
2. MATERIALS AND METHODS 
Correspondence address: A.T. Evans, Department of 
Ph~macognosy, The School of Pharmacy, University 
of London, 29-39 Brunswick Square, London 
WCIN IAX, England 
A ‘-Tetrahydrocannabinol was obtained from 
Sigma, Other c~nabinoids were purchased from 
Makor Chemicals, Tel Aviv. Structures are il- 
lustrated in fig.1. The ability of cannabis con- 
stituents to inhibit the phospholipase A2 of ZVaja 
naja venom (Sigma) was determined using a 
modification of the .spectroscopic technique of 
Wells 151. Acid release was detected by the forma- 
tion of the acidic species of bromoth~ol blue, 
and enzyme activity determined by measuring the 
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Fig. 1. Structures of cannabis constituents. (1) Olivetol, 
(2) cannaflavin A, (3) cannabigerol, (4) cannabidiol, (5) 
cannabinol, (6) A’-tetrahydrocannabinol. 
rate of increase in absorbance at 445 nm. The 
assay mixture contained 50 mM bromothymol 
blue, 5 mM dicapryloyllecithin and 0.05 mM 
CaC12 in a volume of 2 ml. The pH was adjusted 
to 8.0 with NaOH and the reaction initiated by the 
addition of 1 pg enzyme (equivalent to 0.1 units of 
activity). At 3O”C, the reaction rate was linear over 
a range of 0.06 absorbance unit (equivalent to the 
formation of 0.25 pmol acid). Compounds to be 
tested were added to the assay mixture in 10 pl ab- 
solute ethanol prior to the addition of enzyme. 
3. RESULTS 
The effects of cannabinoids on phospholipase 
AZ activity are summarised in table 1 and fig.2. All 
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Fig.2. Stimulation of phospholipase A2 activity by 
cannabinoids. Details of assay conditions are given in 
the text. See also table 1. Acid release in the absence of 
drugs: 0.07 f O.O06~mol/min. 
Table 1 
Biphasic stimulation of phospholipase A2 activity by 
cannabis constituents 
Compound Maximum EGO ICSO 
stimulation 
(%) pg/ml PM pg/ml PM 
Olivetol none - - - - 
THC 316 6.0 19.1 48 153 
CBD 262 2.0 6.4 42 134 
CBN 310 2.0 6.4 41 142 
CBG 160 3.0 9.5 17 55 
Mepacrine -9Oa - - 6.8 14 
a Inhibitory activity 
Acid release from dicapryloyllecithin due to the action 
of phospholipase AZ from Naja naja venom was 
detected using the indicator bromothymol blue. Details 
of assay conditions are given in the text. Acid release in 
the absence of drugs: 0.07 f 0.006 gmol/min. Data are 
the mean of at least two separate experiments 
the compounds tested were potent stimulators of 
enzyme activity, with concentrations producing 
50% maximal stimulation (EC50 values) being in 
the range 5.0-20 x 10m6 M. The response was 
biphasic however, with a decline in activity being 
observed at higher dose levels. Concentrations at 
which enzyme activity had returned to 50% max- 
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Table 2 
Correlation of the effects of cannabinoids on phospholipase As with in 
vitro stimulation of PGE2 release from human synovial cells, and with 
cataleptic activity in mice 
Compound Phospholipase AS PGE2 releasea Cataleptic 
activityb 
% max. Concn % max. Concn 
THC 316 16 330 30 ++ 
CBN 310 12 220 10 0 
CBD 262 10 180 10 0 
CBG 160 9 inhibition - 0 
a Potentiation of TPA-stimulated PGE2 release from human synovial 
cells in vitro [6]. Plastic adherent synovial cells were stimulated to 
release PGE2 with 10 ng/ml TPA, and after 48 h incubation, the PGE2 
content of supernatant fluids was measured by direct 
radioimmunoassay 
b Induction of cataleptic state in mice assessed on an arbitrary scale by 
the ring test [7]. Compounds were administered orally to male CD1 
mice up to maximum tolerated doses, and motor activity assessed by 
counting the number of times unrestrained animals stray outside a 
designated area 
% max., percentage maximum stimulation above controls; Concn, 
concentration @g/ml) of drug at which maximum stimulation was 
observed 
January 1987 
imal (I& values) were in the range 40-150 X 
lOWe’ M. It is noteworthy that THC was the least 
potent of the four compounds tested on the basis 
of ECse values, and although THC produced the 
highest level of stimulation, it was not significantly 
better than either CBD or CBN. 
The results from this cell-free system correlate 
well with the observations of Barrett and co- 
workers [6] who studied the effects of can- 
nabinoids on human synovial cells. They 
demonstrated a biphasic stimulation of PGEz 
release by THC, CBD and CBN, whilst CBG was 
inhibitory. In contrast, we have confirmed that 
THC is unique among the cannabinoids in possess- 
ing cataleptic activity in the ring test [7]. These 
comparisons are summarised in table 2. 
4. DISCUSSION 
Using an in vitro assay, we have observed a 
direct effect of cannabinoids on phospholipase A2 
from Nuja naja venom (fig.2). The use of a short 
chain lecithin as substrate allowed activity to be 
demonstrated without the addition of detergents 
which may affect the action of certain drugs. It is 
significant that mepacrine possesses inhibitory ac- 
tivity in this system (table I), whereas it is generally 
ineffective in hydrolysis procedures using high 
molecular mass lecithins which require solubilisa- 
tion by detergents [8]. The relative potencies of the 
four cannabinoids, THC, CBD, CBN and CBG 
(table 1) correlated well with data previously 
reported for at least one in vitro system (human 
synovial cells) and it may be concluded that 
stimulation of phospholipase AZ is the most signifi- 
cant step in initiation of prostaglandin release. Our 
results resolve the mechanism of action of these 
compounds to three possible sites. Firstly, they 
may affect calcium activation of the enzyme. Since 
the cannabinoids have been shown not to affect the 
activity of another calcium-dependent enzyme, 
protein kinase C (not shown), it is unlikely that 
these compounds exert a unique action on the 
calcium dependence of phospholipase AZ. Second- 
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Iy, the ~phipathic nature of these molecules 
might allow their intercaiation into the substrate 
miceIIe (or protein-phospholipid environment of 
the cell membrane) creating greater availability of 
substrate, followed by enzyme stimulation, and at 
higher concentrations a decrease in effective 
substrate concentrations and inhibition. This is 
also unlikely to be the major mechanism of action 
since stereospecific structurai requirements have 
been reported for activity in cell culture (Burstein, 
S., personal communication). We therefore sug- 
gest that the c~nabinoids interact with a 
hydrophobic reguiating site on phospholipase AZ, 
and that this site is present on both soluble and 
membrane forms of the enzyme. 
A striking feature of these results is the similari- 
ty of the actions of cannabinoids on prostaglandin 
metabolism in vitro, contrasted with the unique 
central effects of THC. Inhibitor studies in vivo 
have produced convincing evidence that PGs are 
involved in mediating the cataleptic response to 
THC in mice [l]. However, PGs play a role in 
regulating the expression of various receptors in 
the brain [9] and recent studies have demonstrated 
a major role of catecholamine pathways in 
mediating behavioural and antinociceptive ffects 
of cannabis [lo, 111. Thus, whilst it is possible that 
the greater stimulatory effect of THC on 
phospholipase AZ in vitro is sufficient to expiain 
the dramatic difference in ph~macoIogica1 pro- 
file, it is more likely that the THC receptor is not 
located in the arachidonate cascade itself, but in a 
pathway which is sensitive to changes in PG levels. 
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